Drug classes used as comedication when beginning DAA therapy, by severity of liver disease, among HCV-infected patients.

<p>Drug classes used as comedication when beginning DAA therapy, by severity of liver disease, among HCV-infected patients.</p

Number of co-medications used and percentage of patients, by DAA regimen, among HCV-infected patients.

<p>(A) Patients with mild liver disease. (B) Patients with moderate-to severe-liver disease. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. The percentage of patients who took one drug (in blu), two drugs (in red), three drugs (in green) and more than 3 drugs (in violet) are reported considering the total number of patients reported for each regimen in both Fig 1A and Fig 1B at the same manner.</p

Category of potential DDIs, by DAA regimen and severity of liver disease, among HCV-infected patients.

<p>Comedication used in patients with mild liver disease (A) or in (B) patients with moderate-to severe-liver disease (B). DAA regiments and number of comedications used are shown. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. Category 0: Classification not possible due to lack of information; Category 1: No clinical interaction possible; Category 2: May require dose adjustment/closer monitoring.</p

The most common drugs with a potential DDI among HCV-infected patients with moderate-to-severe liver disease.

<p>The most common drugs with a potential DDI among HCV-infected patients with moderate-to-severe liver disease.</p

Sociodemographic and virological characteristics and comedications used, by severity of liver disease, among HCV-infected patients undergoing DAA therapy.

<p>Sociodemographic and virological characteristics and comedications used, by severity of liver disease, among HCV-infected patients undergoing DAA therapy.</p

Univariate and logistic regression analysis linking failure with independent variables.

<p>Univariate and logistic regression analysis linking failure with independent variables.</p

Failure rates following the first DAA regimen, by HCV genotype and treatment regimen in patients who completed the 12 weeks post treatment evaluation (n = 3,830 patients).

<p>Failure rates following the first DAA regimen, by HCV genotype and treatment regimen in patients who completed the 12 weeks post treatment evaluation (n = 3,830 patients).</p

Modifications of liver disease stage following DAA treatment in patients with cirrhosis.

<p>(A) Baseline, post-failure and post-retreatment SVR12 changes of Child Pugh Class; (B) baseline and post-failure changes of Child Pugh Class for patients who were not retreated yet; (C) baseline and post-SVR12 changes of Child Pugh Class for patients who achieved SVR12 following the first DAA treatment. Bold arrows indicate patients who did not change the Child Pugh Class. Dashed arrows indicate patients who worsened the Child Pugh Class, whereas the grey arrows indicate patients who improved the Child Pugh class. In the curly brackets are reported the number of patients for specific changes observed in the Child Pugh classes in the three points of evaluation. n = number of patients.</p

Characteristics of the study patients according to SVR following the first DAA treatment.

<p>Characteristics of the study patients according to SVR following the first DAA treatment.</p